Avoiding the DDMAC letter: Advice from a Pfizer counselor

Share this article:
As the FDA keeps up the pressure on marketers for making unsubstantiated claims in their professional promotions, a Pfizer legal expert says companies may be able to avoid such notices by supporting all advertising claims with “substantial evidence.”

In March the Division of Drug Marketing, Advertising and Communications chief Thomas Abrams said he was seeing too many ads that omit or downplay risk information and that his office was stepping up enforcement to put pharmaceutical marketers on notice that they are not beyond reproach for such missteps.

“There appears to be a lack of attention on risk information, as the focus is so much on benefit,” Abrams said at the time.

His ire has spread to unsubstantiated claims. According to the FDA Law Blog, two recent warning letters to Novartis and Pfizer reinforce a DDMAC focus on ensuring that promotional pieces contain substantial evidence to back up ad claims and proper presentations of safety data. “Certainly ‘substantial evidence' is the DDMAC watchword for now and for the foreseeable future,” read a recent post.

The bloggers at food and drug law firm Hyman, Phelps & McNamara, which produces the blog, drew their inspiration from an article by Arnold Friede, Pfizer senior corporate counsel. Even before its most recent missives, DDMAC correspondence over the last few months “clearly indicates that FDA insists on ‘substantial evidence' to support all advertising claims, including, notably, comparative claims (but not limited to comparisons),” wrote Friede in the article published by the Washington Legal Foundation last week.

The Food and Drug Act sets out the definition of “substantial evidence.” It consists of adequate and well-controlled investigations, including clinical investigations—the same standards FDA applies to substantiation for advertising claims on approved products, he wrote.

In a somewhat ironic punctuation to Friede's Aug. 10 article, DDMAC's July untitled letter to Pfizer called the firm on the carpet for making an unsubstantiated superiority claim in promotional materials for Geodon (ziprisadone), its injectable for treating acute agitation in schizophrenic patients, and for leaving out important risk information. Its warning letter this month to Novartis objected to unsubstantiated superiority claims for Alzheimer's treatment Exelon (rivastigmine) made in a promotional card.

Such correspondence must be studied, urged Friede, who had this “simple and relatively straightforward" advice: "If you want to avoid problems with DDMAC, ensure that claims in prescription drug advertising and promotion are supported by 'substantial evidence,' no matter how competent and reliable the supporting evidence might otherwise be to the company and to leading experts in the field. To put it bluntly, DDMAC doesn't really care. What DDMAC cares about is like  'location,' 'location,' 'location' in the real estate purchase context. It's about 'substantial evidence,' 'substantial evidence,' 'substantial evidence.'"

Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.